Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1
Walter Reinisch(Medical University of Vienna), Fabio Cataldi(Pfizer (United States)), Mina Hassan‐Zahraee(Pfizer (United States)), Kenneth E. Hung(Pfizer (United States))
Cited by 61
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
|Gastroenterology|2020|692
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
|The Lancet|2023|350
Guidelines on the use of extracorporeal photopheresis
|Journal of the European Academy of Dermatology and Venereology|2013|218